Form 8-K - Current report:
SEC Accession No. 0001193125-25-019359
Filing Date
2025-02-03
Accepted
2025-02-03 17:05:51
Documents
13
Period of Report
2025-01-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d927659d8k.htm   iXBRL 8-K 38451
  Complete submission text file 0001193125-25-019359.txt   169672

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA omga-20250129.xsd EX-101.SCH 2867
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE omga-20250129_lab.xml EX-101.LAB 18736
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE omga-20250129_pre.xml EX-101.PRE 11718
15 EXTRACTED XBRL INSTANCE DOCUMENT d927659d8k_htm.xml XML 3767
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 25583610
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)